Investigating ROS1 and TRK Rearrangements in Lung Cancer
Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing on <em>ROS1 </em>and <em>TRK </em>mutations.
Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing onROS1andTRKmutations.
ROS1rearrangements are highly actionable, according to Levy. Crizotinib (Xalkori) has been approved by the FDA forROS1rearrangements, but there are many new drugs coming down the pike that are also active, including entrectinib. The next step with these drugs is determining the best sequence, while also understanding the mechanisms of resistance to ROS1, Levy says. Currently, crizotinib is still the standard, though Levy argues that the data from the World Conference on Lung Cancer shows entrectinib may also be considered.
Levy also discusses a recent tissue agnostic basket trial that investigated larotrectinib (LOXO-101) in patients withNTRKfusions. The response rate in this trial was almost 70%. This drug has been exceptionally well tolerated and is the poster child for precision medicine, Levy says.
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
February 17th 2025During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.
Read More
